+10.77 (+4.33%)
Cash Position
-
Monthly Burn
-
Runway
-
locked
| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Long Term Data example | Phase 2 | — | Subscribe to access the data. | Peptides | Endocrine System | ||
Long Term Data example | Phase 2 | — | Subscribe to access the data. | Peptides | Endocrine System | ||
Long Term Data example | Phase 2 | — | Subscribe to access the data. | Peptides | Endocrine System |
Dated clinical, regulatory & corporate events for Ascendis Pharma A/S
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-02-28 | TransCon CNP (navepegritide) | PDUFA Date | PDUFA | Approved | – | – | – |
2026-02-28 | TransCon CNP (navepegritide) | PDUFA Date | PDUFA | Approved | – | – | – |
2026-02-28 | TransCon CNP (navepegritide) | PDUFA Date | PDUFA | Approved | – | – | – |
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lonapegsomatropin Monoclonal antibody | Turner Syndrome | Phase 3 | NCT05690386 | 62% | $2.9B | ACTIVE NOT_RECRUITING | 234 | SLOW | C (48) | Dec 1, 2027 | LOW_RISK | May 13, 2026 |
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
TransCon CNP and TransCon hGH Priority | achondroplasia | Phase 2 | 2026-08-06 | mean AGV at Week 78 was 7.73 cm/year; increase in mean ACH height Z-score of +1.29, increasing from 0.46 to 1.75 over 78 weeks; mean AGV at Week 78 was 7.67 cm/year; improvement in mean ACH height Z-score of +1.10, increasing from 1.28 to 2.38 over 78 weeks Read More | Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S. Read More | |
TransCon CNP and TransCon hGH Priority | achondroplasia | Phase 2 | 2026-08-06 | mean AGV at Week 78 was 7.73 cm/year; increase in mean ACH height Z-score of +1.29, increasing from 0.46 to 1.75 over 78 weeks; mean AGV at Week 78 was 7.67 cm/year; improvement in mean ACH height Z-score of +1.10, increasing from 1.28 to 2.38 over 78 weeks Read More | Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S. Read More | |
TransCon CNP and TransCon hGH Priority | achondroplasia | Phase 2 | 2026-08-06 | mean AGV at Week 78 was 7.73 cm/year; increase in mean ACH height Z-score of +1.29, increasing from 0.46 to 1.75 over 78 weeks; mean AGV at Week 78 was 7.67 cm/year; improvement in mean ACH height Z-score of +1.10, increasing from 1.28 to 2.38 over 78 weeks Read More | Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S. Read More |
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Ascendis Pharma reported a significant increase in product revenue for Q2 2026, totaling €315 million, driven by strong sales of YORVIPATH, SKYTROFA, and YUVIWEL. The company highlighted successful trial data presentations and completion of key enrollment milestones. Ascendis also settled its convertible notes and was added to multiple Russell U.S. Indexes, indicating a strong market position.
Read more →Ascendis Pharma A/S announced plans to report its second quarter 2026 financial results and provide a business update on August 13, 2026. A conference call will follow the report, allowing investors to engage with the company. The announcement highlights Ascendis' commitment to transparency and innovation in addressing patient needs.
Read more →Ascendis Pharma announced positive results from the Phase 2 COACH Trial, showing significant growth improvements in children with achondroplasia using TransCon CNP and TransCon hGH combination therapy. The company also reported successful enrollment in the pivotal reACHin Trial for infants and noted a strong uptake of YUVIWEL in the U.S., with over 65% of patients approved for reimbursement.
Read more →Ascendis Pharma reported positive results from the ApproaCH Trial, showing that children with achondroplasia treated with TransCon CNP demonstrated sustained improvements in lower extremity alignment over 104 weeks. The trial highlighted significant reductions in tibial-femoral angle, particularly in children with preexisting genu varum. The treatment was well tolerated, with no serious adverse events reported.
Read more →Ascendis Pharma A/S has announced its inclusion in several Russell U.S. Indexes, including the Russell 3000, Russell 1000, Russell 2500, and Russell Midcap. This change is effective as of June 26, 2026, and reflects the company's growing market presence. The Russell Indexes are widely utilized by investment managers, indicating potential for increased investment interest.
Read more →Ascendis Pharma will present new data on treatments for achondroplasia at ICCBH 2026. The presentations include Week 104 data from the pivotal ApproaCH Trial and findings from the COACH Trial. These results highlight the benefits of TransCon CNP and its combination with TransCon hGH, addressing significant unmet needs in affected children.
Read more →Ascendis Pharma announced positive results from the Phase 3 PaTHway Trial of TransCon PTH, showing sustained efficacy and safety in adults with hypoparathyroidism over 182 weeks. The treatment replicated the actions of endogenous PTH, leading to significant improvements in kidney function and quality of life. An impressive 89% of patients completed the trial, with no new safety concerns reported.
Read more →Ascendis Pharma A/S will present new data on its Endocrinology Rare Disease programs at ENDO 2026 in Chicago. The presentations will cover treatments for hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency. The company emphasizes the long-term safety and efficacy of its therapies, particularly TransCon PTH and TransCon CNP.
Read more →Ascendis Pharma A/S reported strong financial results for Q1 2026, achieving a revenue of 197 million for YORVIPATH and 44 million for SKYTROFA. The company noted over 1,000 new patient enrollments for YORVIPATH in the U.S. and a substantial net profit of 629 million, a significant improvement from the previous year's loss. Despite these positive outcomes, there was an increase in total operating and net finance expenses compared to the same quarter last year. Ascendis continues to expand its market presence and innovations in biopharmaceuticals.
Read more →Ascendis Pharma reported strong financial results for Q1 2026, with total revenue reaching €247 million, driven primarily by YORVIPATH. The company also noted significant patient enrollments for both YORVIPATH and YUVIWEL, the latter of which received FDA accelerated approval. Despite increased operating expenses, the overall outlook remains positive as Ascendis continues to expand its market presence.
Read more →Ascendis Pharma announced new data from the ApproaCH Trial, showing that children with achondroplasia aged 5 years and older treated with TransCon CNP exhibited significant annualized growth velocity improvements compared to placebo. The safety profile remained consistent over two years, with mild injection site reactions and no serious adverse effects. These findings reinforce the drug's potential in promoting healthy growth in affected children.
Read more →Ascendis Pharma A/S announced it will report its first quarter 2026 financial results and provide a business update on May 7, 2026. The company will host a conference call and live webcast at 8:00 a.m. ET on the same day. This event aims to engage investors and share insights on their innovative TransCon technology platform.
Read more →Ascendis Pharma A/S has announced the redemption of all $575 million of its outstanding 2.25% Convertible Senior Notes due 2028, effective May 6, 2026. This decision follows the last reported sale price per ordinary share exceeding 130% of the conversion price for a specified period. Holders can convert their notes before the redemption date, with an increased conversion rate during the Make-Whole Conversion Period.
Read more →Ascendis Pharma A/S has commenced trading of its ordinary shares on the Nasdaq Global Select Market, replacing its previous listing of American Depositary Shares (ADSs). The ordinary shares will continue to trade under the ticker symbol 'ASND'. The company has successfully exchanged all outstanding ADSs for ordinary shares as of April 20, 2026.
Read more →Ascendis Pharma announced that YUVIWEL (navepegritide) has received orphan drug exclusivity from the FDA and is now commercially available in the U.S. This once-weekly treatment aims to enhance linear growth in pediatric patients with achondroplasia. The company has initiated therapy for several patients and established a support program for caregivers. YUVIWEL's orphan drug exclusivity will last until February 2033.
Read more →Ascendis Pharma announced positive Week 52 results from the New InsiGHTS trial, showing that TransCon hGH (lonapegsomatropin) is as effective as daily somatropin in treating Turner syndrome in children. The trial involved 49 prepubertal children and demonstrated similar annualized height velocity and safety profiles. No significant adverse events were reported, supporting the potential of TransCon hGH as a differentiated therapy.
Read more →Ascendis Pharma presented new two-year data from the ApproaCH Trial at ACMG 2026, demonstrating that children with achondroplasia treated with TransCon CNP maintained significant growth improvements. The treatment was well-tolerated, with no severe adverse events reported. The FDA approved TransCon CNP for increasing linear growth in pediatric patients, with EMA review pending.
Read more →Ascendis Pharma A/S announced its participation in the TD Cowen 46th Annual Health Care Conference, scheduled for March 2, 2026. Company executives will engage in a virtual fireside chat, which will be accessible via a live webcast. The event highlights Ascendis' commitment to innovative therapies using its TransCon technology platform.
Read more →Ascendis Pharma announced that the FDA has approved YUVIWEL (navepegritide) as the first once-weekly treatment for children aged 2 and older with achondroplasia. This approval, granted under the Accelerated Approval Program, is based on improvements in annualized growth velocity from clinical trials. YUVIWEL aims to provide continuous exposure to CNP, addressing the overactive FGFR3 signaling associated with the condition. The company plans to make YUVIWEL available in early Q2 2026, along with patient support services.
Read more →Ascendis Pharma A/S has announced its Annual General Meeting scheduled for March 23, 2026, in Copenhagen, Denmark. Key agenda items include the re-election of current board members, the introduction of new member Jean-Jacques Bienaim, and the approval of the company's audited annual report. Additionally, the board proposes to carry forward a significant consolidated loss of EUR 228 million into the next fiscal year. Shareholders are invited to submit questions and participate either in person or by proxy.
Read more →Ascendis Pharma A/S announced its financial results for Q4 and the full year 2025, showing substantial revenue growth driven by its product YORVIPATH. The company reported total revenues of €720 million for 2025, up from €364 million in 2024. Despite a net loss of €228 million, Ascendis is optimistic about its growth trajectory and aims for €5 billion in annual product revenue by 2030.
Read more →Ascendis Pharma reported its financial results for Q4 and full-year 2025, revealing a product revenue of $240 million for the quarter and $684 million for the year. The company anticipates strong growth moving forward, expecting to generate approximately $500 million in operating cash flow for 2026, with a global revenue target of at least $5 billion by 2030. Although the company continues to report net losses, it sees potential in its growing pipeline and recent product advancements, notably the TransCon CNP under FDA Priority Review. Overall, Ascendis Pharma is positioning itself for a significant growth phase in the biopharma sector.
Read more →Pendopharm has received Health Canada's approval for Yorvipath® (palopegteriparatide injection), a new treatment for chronic hypoparathyroidism in adults. This approval follows a distribution agreement with Ascendis Pharma, which has already secured approvals in several other countries. The launch aims to improve treatment options for Canadian patients suffering from this condition.
Read more →Ascendis Pharma A/S plans to report its full year 2025 financial results and provide a business update on February 11, 2026. The company will host a conference call and live webcast at 4:30 p.m. ET on the same day. Ascendis aims to utilize its TransCon technology to develop innovative therapies, although it faces various operational risks.
Read more →Ascendis Pharma A/S announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, scheduled for January 12, 2026. Company executives will provide a business update during the event, which will be accessible via a live webcast. The company emphasizes its commitment to innovation through its TransCon technology platform, aimed at addressing unmet medical needs.
Read more →Ascendis Pharma announced that the FDA has extended the PDUFA goal date for TransCon CNP (navepegritide) by three months to February 28, 2026. This extension follows the submission of additional information related to post-marketing requirements. The company is committed to working with the FDA to finalize these requirements and expedite the therapy's availability for children with achondroplasia.
Read more →Ascendis Pharma announced positive results from the pivotal ApproaCH Trial of TransCon CNP (navepegritide) in children with achondroplasia. The trial demonstrated significant improvements in annualized growth velocity and health-related quality of life compared to placebo. The treatment was well-tolerated, showing a safety profile comparable to placebo. TransCon CNP is currently under FDA Priority Review.
Read more →Ascendis Pharma reported a strong financial performance for Q3 2025, with total revenue reaching €213.6 million, significantly up from €57.8 million in Q3 2024. The growth was largely driven by the successful launch of YORVIPATH. The company also reported an operating profit of €11.0 million, although it faced a net loss of €61.0 million. TransCon CNP is currently under FDA Priority Review, with a PDUFA date set for November 30, 2025.
Read more →Ascendis Pharma reported third quarter 2025 financial results, highlighting revenues of 143.1 million from YORVIPATH and 50.7 million from SKYTROFA. The company achieved an operating profit of 11.0 million, reflecting a significant increase in overall revenue compared to the previous year. Furthermore, TransCon CNP is currently under FDA and EMA review, with expectations for a potential market introduction. Despite the positive revenue growth, Ascendis Pharma also reported a net loss of 61.0 million for the quarter, although this was an improvement from the previous year.
Read more →Ascendis Pharma announced a pooled analysis confirming significant improvements in renal function for adults with hypoparathyroidism treated with TransCon PTH over three years. The analysis, presented at Kidney Week 2025, showed that 70.3% of patients experienced clinically meaningful increases in eGFR. The treatment was well tolerated, with most adverse events being mild to moderate.
Read more →Ascendis Pharma has submitted a Marketing Authorisation Application for TransCon CNP to the EMA, aimed at treating children with achondroplasia. This investigational drug has shown positive results in clinical trials, demonstrating good tolerance among participants. The company is eager to engage with the EMA for a swift review process, while also awaiting FDA approval in the U.S.
Read more →Ascendis Pharma A/S announced three oral presentations at ASBMR 2025, showcasing new data on achondroplasia and hypoparathyroidism. The presentations include pivotal trial data correlating leg bowing improvements with physical functioning in children and long-term skeletal dynamics in adults. The company emphasizes the transformative potential of its therapies.
Read more →Ascendis Pharma A/S will participate in the 2025 Wells Fargo Healthcare Conference on September 3, 2025. Executives will engage in a fireside chat, and a live webcast will be available for investors. The company emphasizes its commitment to innovative therapies through its TransCon technology platform, although it acknowledges associated risks in its forward-looking statements.
Read more →Ascendis Pharma announced its financial results for Q2 2025, reporting total revenue of 158 million, driven largely by YORVIPATH sales. The company is optimistic about its future with TransCon CNP under U.S. FDA Priority Review, expected to fulfill unmet medical needs in endocrine rare diseases. Despite a significant year-over-year revenue increase, Ascendis also reported a net loss of 38.9 million. The company continues to expand its commercial portfolio, including planned label expansions for SKYTROFA.
Read more →Ascendis Pharma announced that the FDA has approved SKYTROFA (lonapegsomatropin-tcgd) for treating adults with growth hormone deficiency (GHD). This approval is based on the Phase 3 foresiGHt trial, which demonstrated the efficacy and safety of the once-weekly injection. The new treatment option aims to enhance patient adherence compared to traditional daily injections.
Read more →Ascendis Pharma reported promising interim topline data from the Phase 2 COACH Trial, evaluating a combination of TransCon CNP and TransCon hGH in children with achondroplasia. The results at Week 26 showed a mean annualized growth velocity of 9.14 cm/year for the treatment-naive cohort and improvements in height Z-scores. Notably, the combination therapy appears to enhance growth outcomes while maintaining a safety profile consistent with existing treatments. Further data is anticipated as the trial progresses.
Read more →Ascendis Pharma has reported its financial results for Q1 2025, highlighting a total revenue increase to 101 million, driven by strong sales of YORVIPATH. The company anticipates an inflection point in 2025 with ongoing development of TransCon CNP, expected for approval in children with achondroplasia. However, the quarter also featured a net loss of 94.6 million, largely due to rising operational expenses. The firm plans to submit a marketing authorization application for TransCon CNP in Q3 2025 and is optimistic about its future pipeline and prospects.
Read more →Ascendis Pharma A/S has announced its Annual General Meeting (AGM) for 2025, scheduled for May 27th at 2:00 PM CET in Copenhagen, Denmark. The agenda includes the re-election of board members, the appointment of Deloitte as the company's auditor, and various proposals regarding capital increases and amendments to the articles of association. Shareholders will also have an opportunity to submit questions regarding the agenda. The meeting aims to address the company’s financial activities for the year ended December 31, 2024.
Read more →Ascendis Pharma has reported strong financial results for the fourth quarter and full year 2024, highlighted by the early launch of YORVIPATH, which achieved 908 prescriptions. The company anticipates submitting an NDA for TransCon CNP for treating achondroplasia in children by Q1 2025. Despite a net loss of 378.1 million for the year, Ascendis experienced significant revenue growth, attributed to an upfront payment from Novo Nordisk and increased commercial product sales. The company aims to leverage its cash reserves and partnerships to bolster its position in the biopharmaceutical market.
Read more →Ascendis Pharma presented its strategic updates at the J.P. Morgan Healthcare Conference, highlighting its robust portfolio in endocrinology and rare diseases. The company anticipates significant revenue growth, particularly with products like SKYTROFA and YORVIPATH. Ascendis is also focused on expanding its TransCon technology platform and pursuing collaborations to maximize market opportunities. Despite optimistic projections, the presentation noted inherent risks tied to the forward-looking statements regarding regulatory approvals and market conditions.
Read more →Ascendis Pharma has reported its financial results for Q3 2024, showcasing a revenue increase attributable to the recent launch of YORVIPATH, which delivered 8.5 million in ex-U.S. revenue. The company also announced a collaboration with Novo Nordisk aimed at developing new therapies. Despite these positive developments, Ascendis experienced a significant net loss of 99.2 million in Q3, highlighting challenges in managing high operating expenses. Upcoming submissions for TransCon CNP are planned for early 2025, reflecting ongoing investment in product development.
Read more →The ApproaCH Trial for TransCon CNP, an investigational product candidate for achondroplasia, achieved its primary objective by demonstrating a statistically significant increase in annualized growth velocity compared to placebo. The treatment not only provided catch-up growth in children aged 2 to 11 years but also showed improvements in health-related quality of life. TransCon CNP was generally well-tolerated with minimal adverse events, suggesting its potential as a safe and effective treatment option for children with skeletal dysplasias.
Read more →Ascendis Pharma has reported its financial results for Q2 2024, revealing a total revenue of 36 million, down from 47.4 million in Q2 2023. The FDA has approved YORVIPATH, the first treatment for hypoparathyroidism in adults, showcasing the company's commitment to addressing unmet needs in rare diseases. Nevertheless, the company faced adjustments to previous sales estimates that negatively impacted revenue. Ascendis also reported a net loss of 109.4 million but indicated a positive outlook for SKYTROFA with expectations of reaching blockbuster status.
Read more →The FDA has approved YORVIPATH (palopegteriparatide) as the first treatment for hypoparathyroidism in adults, addressing significant unmet medical needs. Ascendis Pharma plans to provide patient support services and anticipates product availability in early 2025.
Read more →Ascendis Pharma A/S announced its Annual General Meeting (AGM) scheduled for May 30, 2024, at its Copenhagen location. The agenda includes reports from the board members, proposals for the adoption of the annual report, and re-elections for Class II board members. Notably, the board recommends renewing its authorization to increase share capital while addressing a significant reported loss for the fiscal year 2023.
Read more →Ascendis Pharma reported its first quarter financial results for 2024, showcasing a significant revenue increase to 95.9 million, primarily driven by SKYTROFA sales. The company initiated the rollout of its YORVIPATH product in Germany and Austria, with positive early adoption from physicians and patients. Despite increased revenue, Ascendis reported a higher net loss, reflecting ongoing expenditures in research and development. The company remains optimistic about achieving quarterly cash flow breakeven by the end of the year.
Read more →Ascendis Pharma reported its financial results for the fourth quarter and full year of 2023, highlighting a total revenue of 138 million in Q4, driven by strong sales of SKYTROFA. The company announced the commercial launch of TransCon PTH in Germany and Austria, with a U.S. PDUFA date scheduled for May 14, 2024. However, despite a year-over-year improvement in net loss, Ascendis continues to grapple with high operating expenses. As part of its strategic goals, Ascendis is aiming for blockbuster status for its main products and has streamlined its operations.
Read more →Ascendis Pharma announced its third quarter 2023 financial results, highlighting significant revenue growth driven by SKYTROFA sales. The company expects a European Commission decision for TransCon PTH soon, with plans for a launch in Germany in January 2024, if approved. However, they reported a net loss of $162.2 million as R&D costs rose, driven by increased clinical trial activities. The company also initiated new clinical trials, indicating ongoing investment in their product pipeline.
Read more →Ascendis Pharma has released its financial results for Q2 2023, reporting a substantial revenue increase driven by SKYTROFA sales. The company expects to resubmit its New Drug Application for TransCon PTH to the FDA in October 2023, with a decision from the European Commission on its Marketing Authorization Application expected by the end of the year. Ascendis has also completed enrollment for a pivotal Phase 3 trial of TransCon CNP, aiming for topline results in late 2024. Despite raising revenue expectations, the company reported a notable net loss in the quarter, attributed to higher R&D and operational costs.
Read more →Ascendis Pharma A/S has announced its Annual General Meeting (AGM) to be held on May 30th, 2023, in Copenhagen, Denmark. The meeting will cover various agenda items including the re-elections of Class I board members and the appointment of Deloitte as the auditor. A consolidated loss of EUR 583.2 million for the year 2022 will be carried forward to next year. Shareholders will have options for participating in the meeting both physically and electronically, with specific details provided on the company's website.
Read more →The FDA issued a complete response letter for Ascendis Pharma's TransCon PTH, citing manufacturing concerns but not requiring additional clinical trials. Ascendis plans to collaborate with the FDA to address these issues and expedite availability for patients with hypoparathyroidism.
Read more →Ascendis Pharma announced its first quarter 2023 financial results, focusing on bringing TransCon PTH to market in the U.S. and EU. Despite reporting a net loss of $110.9 million, there was a notable increase in SKYTROFA revenue, which reached $31.6 million. The company aims to achieve cash flow breakeven without resorting to additional dilutive equity financing. Ascendis continues to support ongoing clinical trials and has committed to enhancing patient lives through its innovative therapies.
Read more →Ascendis Pharma released its financial results for the full year 2022, showing a revenue increase to $51.2 million compared to $7.8 million in 2021. The company reported a net loss of $583.2 million, up from a previous loss of $383.6 million. Key upcoming milestones include the PDUFA date for TransCon PTH on April 30, 2023, and a planned launch of TransCon hGH in Germany in the third quarter of 2023. The company is also initiating Phase 2b trials for TransCon CNP in achondroplasia, further expanding its therapeutic pipeline.
Read more →Ascendis Pharma A/S presented at the 41st Annual J.P. Morgan Healthcare Conference, focusing on their developments in biopharma. They highlighted their strong financial standing and emphasized the potential of their approved product, SKYTROFA, for pediatric growth hormone deficiency. The company shared their strategic vision for sustainable growth and advancing their diverse pipeline across endocrinology and oncology. Given the challenges of biopharma development, they cautioned about the uncertainties involved in future trials and approvals.
Read more →TransCon CNP ACcomplisH Trial Topline Results November 14, 2022 TransCon CNP is an investigational product candidate. For investor communication only. Not for use in product promotion. Not for further distribution. Cautionary Note on Forward-Looking Statements This presentation
Read more →Ascendis Pharma Reports Third Quarter 2022 Financial Results SKYTROFA U.S. revenue more than doubled quarter-to-quarter again, reaching 12.3 million in the third quarter FDA accepted for Priority Review TransCon PTH NDA in adult patients with hypoparathyroidism; target action
Read more →Notice to convene Extraordinary General Meeting Notice is hereby given that an extraordinary general meeting of Ascendis Pharma A/S (the Company ) will be held on: 9 September 2022 at 2:00 pm CET general meeting will be held at: Mazanti-Andersen Advokatpartnerselskab, Amalieg
Read more →Ascendis Pharma A/S Reports Second Quarter 2022 Financial Results U.S. regulatory submission for TransCon PTH, designed to be the first parathyroid hormone replacement therapy, on track for Q3 2022; EU submission planned for Q4 2022 SKYTROFA revenue continued to double quarter
Read more →INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Interim Statements of Profit or Loss and Other Comprehensive Income / (Loss) for the Three Months Ended March 31, 2022 and 2021 2 Unaudited Condensed Consolidated I
Read more →Notice to convene Annual General Meeting 2022 Notice is hereby given that the annual general meeting of Ascendis Pharma A/S (the Company ) will be held on: May 30th, 2022 at 2:00 pm CET The annual general meeting will be held at: Mazanti-Andersen, Amaliegade 10, DK-1256 Copen
Read more →Ascendis Pharma A/S Reports First Quarter 2022 Financial Results Phase 3 PaTHway Trial top-line results demonstrated potential of TransCon PTH to become the first parathyroid replacement therapy for adults with hypoparathyroidism TransCon PTH U.S. FDA regulatory submission on t
Read more →Ascendis Pharma Announces Proposed Convertible Senior Notes Offering COPENHAGEN, Denmark, March 23, 2022 (GLOBE NEWSWIRE) Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create new product candidates that add
Read more →Ascendis Pharma A/S Reports Full Year 2021 Financial Results and Provides a Business Update Top-line results from PaTHway, a Phase 3 randomized study evaluating the safety, tolerability, and efficacy of TransCon PTH in adult hypoparathyroidism (HP) patients on track for this
Read more →Welcome & Agenda Overview Scott T. Smith Senior Vice President, Chief Financial Officer Cautionary Note on Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation,
Read more →Ascendis Pharma A/S Reports Third Quarter 2021 Financial Results SKYTROFA (lonapegsomatropin-tcgd) approved by the FDA in the U.S. as a once-weekly treatment for pediatric growth hormone deficiency (GHD); commercially launched in October 2021. enrollment in Phase 3 PaTHway Tri
Read more →Notice to convene Extraordinary General Meeting Notice is hereby given that an extraordinary general meeting of Ascendis Pharma A/S (the Company ) will be held on: 18 November 2021 at 2:00 pm CET general meeting will be held at: Mazanti-Andersen Kors Jensen, Amaliegade 10, DK
Read more →Ascendis Pharma A/S Reports Second Quarter 2021 Financial Results Announced U.S. Food and Drug Administration Approval of SKYTROFA (lonapegsomatropin-tcgd), the First Once-weekly Treatment for Pediatric Growth Hormone Deficiency target enrollment in Phase 3 PaTHway Trial for T
Read more →Ascendis Pharma A/S TransConTM PTH - 58-Week Open-Label Extension (OLE) Update May 10, 2021 All product candidates are investigational. For investor communication only. Not for use in promotion or product commercialisation. Exhibit 99.1 Cautionary Note On Forward-Looking State
Read more →Notice to convene Annual General Meeting 2021 Notice is hereby given that the annual general meeting of Ascendis Pharma A/S (the Company ) will be held on: May 28th, 2021 at 2:00 pm CET The annual general meeting will be held at: Mazanti-Andersen, Amaliegade 10, DK-1256 Copen
Read more →Ascendis Pharma A/S Reports Full Year 2020 Financial Results Preparations for potential launch of first Endocrinology Rare Disease product candidate, TransCon hGH (lonapegsomatropin), Oncology pipeline advancing into clinical trials beginning with TransCon TLR7/8 Agonist Confe
Read more →Notice to convene Annual General Meeting 2020 Notice is hereby given that the annual general meeting of Ascendis Pharma A/S (the Company ) will be held on: May 29th, 2020 at 2:00 pm CET The annual general meeting will be held at: Kors Jensen, Amaliegade 10, DK-1256 Copenhagen
Read more →Ascendis Pharma A/S Reports Full-Year 2019 Financial Results On track with 2020 corporate milestones Top-line data from PaTH Forward phase 2 trial on track for Conference call today at 4:30 p.m. Eastern Time COPENHAGEN, Denmark, April 1, 2020 (GLOBE NEWSWIRE) Ascendis Pharma
Read more →Notice to convene Annual General Meeting 2019 Notice is hereby given that the annual general meeting of Ascendis Pharma A/S (the Company ) will be held on: May 29th, 2019 at 2:00 pm CET The annual general meeting will be held at: Mazanti-Andersen Kors Jensen, Amaliegade 10, D
Read more →Ascendis Pharma A/S Reports Full Year 2018 Financial Results Rare disease endocrinology pipeline continues to advance, with significant 2019 milestones anticipated Phase 3 heiGHt Trial results showcase potential of TransCon support company algorithm for product innovation Co
Read more →Notice to convene Extraordinary General Meeting Notice is hereby given that an extraordinary general meeting of Ascendis Pharma A/S (the Company ) will be held on: 02 November 2018 at 2:00 pm CET meeting will be held at: Mazanti-Andersen Kors Jensen, Amaliegade 10, DK-1256 Co
Read more →Notice to convene Annual General Meeting 2018 Notice is hereby given that the annual general meeting of Ascendis Pharma A/S (the Company ) will be held on: May 29th, 2018 at 2:00 pm CET The annual general meeting will be held at: Mazanti-Andersen Kors Jensen, Amaliegade 10, D
Read more →Ascendis Pharma A/S Reports Full Year 2017 Financial Results - Rare Disease Endocrinology Pipeline Advances, with Significant Milestones Anticipated Over the Next Twelve Months - - Conference Call Today at 4:30 p.m. Eastern Time - COPENHAGEN, Denmark, March 28, 2018 (GLOBE NE
Read more →Ascendis Pharma A/S January 2018 Cautionary Note On Forward-Looking Statements: This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, such as statements regarding our future results of ope
Read more →Notice to convene Annual General Meeting 2017 Notice is hereby given that the annual general meeting of Ascendis Pharma A/S (the Company ) will be held on: May 24th, 2017 at 2:00 pm CET The annual general meeting will be held at: Kors Jensen, Amaliegade 10, DK-1256 Copenhagen
Read more →Ascendis Pharma A/S Reports Full Year 2016 Financial Results - Company Expanded Pipeline and Initiated Phase 3 Trial for Lead Product Candidate, TransCon Growth Hormone - - Conference Call Today at 4:30 p.m. Eastern Time - COPENHAGEN, Denmark, March 22, 2017/ PR Newswire/ Asc
Read more →Regarding Forward-Looking Statements This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on our management s beliefs and a
Read more →Notice to convene Annual General Meeting 2016 Notice is hereby given that the annual general meeting of Ascendis Pharma A/S (the Company ) will be held on: May 24, 2016 at 2:00 pm CET The annual general meeting Mazanti-Andersen Kors Jensen, Amaliegade 10, DK-1256 Copenhagen K
Read more →Ascendis Pharma A/S Reports Full Year 2015 Financial Results Copenhagen, Denmark, April 14, 2016/ PR Newswire/ Ascendis Pharma A/S (Nasdaq: ASND), a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs,
Read more →INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Interim Statements of Profit or Loss and Other Comprehensive Income for the Three and Nine Months Ended September 30, 2015 and 2014 2 Unaudited Condensed Consolidat
Read more →A Phase 2, six-month, randomized, active-controlled, safety and efficacy study of TransCon hGH compared to daily hGH in children with Growth Hormone Deficiency (GHD) Pierre Chatelain 1 , MD; Oleg Malievsky 2 , MD; Klaudziya Radziuk 3 , MD; Ganna Senatorova 4 , MD; Michael Beckert
Read more →INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Interim Statements of Profit or Loss and Other Comprehensive Income for the Three and Six Months Ended June 30, 2015 and 2014 2 Unaudited Condensed Consolidated Int
Read more →INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Statements of Profit or Loss and Other Comprehensive Income for the Three Months Ended March 31, 2015 and 2014 2 Unaudited Condensed Consolidated Statements of Fina
Read more →KIGS 12 month HV No statistical comparison conducted between the two studies Genotropin (KIGS) Prescribed 0.22 mg/kg/wk TransCon hGH 0.21 mg/kg/wk 19 Q2 2015 LONG ACTING GROWTH HORMONE PROGRAMS 20 Ascendis Versartis OPKO Novo Height velocity 11.9 14.5 cm As daily hGH 8.7 cm No ac
Read more →Notice to convene Annual General Meeting 2015 Notice is hereby given that the annual general meeting of Ascendis Pharma A/S (the Company ) will be held on: April 23, 2015 at 2:00 pm CET meeting will be held at: Mazanti-Andersen Kors Jensen, Amaliegade 10, DK-1256 Copenhagen K
Read more →Ascendis Pharma A/S Reports Full Year 2014 Financial Results Conference call scheduled for 4:30 PM Eastern time today Copenhagen, Denmark, March 25, 2015/ PR Newswire/ Ascendis Pharma A/S (Nasdaq: ASND), a clinical stage biotechnology company that applies its innovative TransC
Read more →LBT-078 Six-Month Interim Safety and Efficacy of Different Dose Levels of TransCon hGH Administered Once-weekly Versus Standard Daily Human Growth Hormone Replacement Therapy in Pre-Pubertal Children with Growth Hormone Deficiency (GHD) Pierre Chatelain 1 , MD, Oleg Malievsky
Read more →